Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

The "Growing" Reality of the Neurological Complications of Global "Stem Cell Tourism".

Julian K, Yuhasz N, Hollingsworth E, Imitola J.

Semin Neurol. 2018 Apr;38(2):176-181. doi: 10.1055/s-0038-1649338. Epub 2018 May 23.

PMID:
29791943
2.

Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center.

Alldredge B, Jordan A, Imitola J, Racke MK.

Clin Neuropharmacol. 2018 Mar/Apr;41(2):56-59. doi: 10.1097/WNF.0000000000000268.

PMID:
29389745
3.

Elevated expression of granulocyte-macrophage colony-stimulating factor receptor in multiple sclerosis lesions.

Imitola J, Rasouli J, Watanabe F, Mahajan K, Sharan AD, Ciric B, Zhang GX, Rostami A.

J Neuroimmunol. 2018 Apr 15;317:45-54. doi: 10.1016/j.jneuroim.2017.12.017. Epub 2017 Dec 22.

PMID:
29290406
4.

A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants.

Ryan KJ, White CC, Patel K, Xu J, Olah M, Replogle JM, Frangieh M, Cimpean M, Winn P, McHenry A, Kaskow BJ, Chan G, Cuerdon N, Bennett DA, Boyd JD, Imitola J, Elyaman W, De Jager PL, Bradshaw EM.

Sci Transl Med. 2017 Dec 20;9(421). pii: eaai7635. doi: 10.1126/scitranslmed.aai7635.

5.

PRMT5 as a druggable target for glioblastoma therapy.

Banasavadi-Siddegowda YK, Welker AM, An M, Yang X, Zhou W, Shi G, Imitola J, Li C, Hsu S, Wang J, Phelps M, Zhang J, Beattie CE, Baiocchi R, Kaur B.

Neuro Oncol. 2018 May 18;20(6):753-763. doi: 10.1093/neuonc/nox206.

PMID:
29106602
6.

iPhemap: an atlas of phenotype to genotype relationships of human iPSC models of neurological diseases.

Hollingsworth EW, Vaughn JE, Orack JC, Skinner C, Khouri J, Lizarraga SB, Hester ME, Watanabe F, Kosik KS, Imitola J.

EMBO Mol Med. 2017 Dec;9(12):1742-1762. doi: 10.15252/emmm.201708191.

7.

Selection of Patients With Multiple Sclerosis to Undergo Autologous Hematopoietic Stem Cell Transplantation.

Racke MK, Imitola J.

JAMA Neurol. 2017 Apr 1;74(4):392-394. doi: 10.1001/jamaneurol.2016.5925. No abstract available.

PMID:
28241157
8.

Big-Data-Driven Stem Cell Science and Tissue Engineering: Vision and Unique Opportunities.

Del Sol A, Thiesen HJ, Imitola J, Carazo Salas RE.

Cell Stem Cell. 2017 Feb 2;20(2):157-160. doi: 10.1016/j.stem.2017.01.006.

9.

Endogenous repair and development inspired therapy of neurodegeneration in progressive multiple sclerosis.

Hollingsworth E, Khouri J, Imitola J.

Expert Rev Neurother. 2017 Jun;17(6):611-629. doi: 10.1080/14737175.2017.1287564. Epub 2017 Feb 8. Review.

PMID:
28128996
10.

Correction: Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity.

Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE.

Dis Model Mech. 2016 Sep 1;9(9):1063-5. doi: 10.1242/dmm.027235. No abstract available.

11.

Cortical Volume Loss and Neurologic Dysfunction in Multiple Sclerosis.

Racke MK, Imitola J.

JAMA Neurol. 2016 Aug 1;73(8):910-2. doi: 10.1001/jamaneurol.2016.1535. No abstract available.

PMID:
27295341
12.

PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.

Banasavadi-Siddegowda YK, Russell L, Frair E, Karkhanis VA, Relation T, Yoo JY, Zhang J, Sif S, Imitola J, Baiocchi R, Kaur B.

Oncogene. 2017 Jan 12;36(2):263-274. doi: 10.1038/onc.2016.199. Epub 2016 Jun 13.

13.

Deletion 2q37 syndrome: Cognitive-behavioral trajectories and autistic features related to breakpoint and deletion size.

Fisch GS, Falk RE, Carey JC, Imitola J, Sederberg M, Caravalho KS, South S.

Am J Med Genet A. 2016 Sep;170(9):2282-91. doi: 10.1002/ajmg.a.37782. Epub 2016 Jun 9.

PMID:
27282419
14.

Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.

Grewal J, Dalal P, Bowman M, Kaya B, Otero JJ, Imitola J.

J Neurovirol. 2016 Oct;22(5):683-687. Epub 2016 Jun 6.

PMID:
27273076
15.

Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity.

Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE.

Dis Model Mech. 2016 Feb;9(2):199-210. doi: 10.1242/dmm.022921. Epub 2015 Dec 10. Erratum in: Dis Model Mech. 2016 Sep 1;9(9):1063-5.

16.

Responsibilities of Health Care Professionals in Counseling and Educating Patients With Incurable Neurological Diseases Regarding "Stem Cell Tourism": Caveat Emptor.

Bowman M, Racke M, Kissel J, Imitola J.

JAMA Neurol. 2015 Nov;72(11):1342-5. doi: 10.1001/jamaneurol.2015.1891.

PMID:
26322563
17.

A novel 2q37 microdeletion containing human neural progenitors genes including STK25 results in severe developmental delay, epilepsy, and microcephaly.

Imitola J, Khurana DS, Teplyuk NM, Zucker M, Jethva R, Legido A, Krichevsky AM, Frangieh M, Walsh CA, Carvalho KS.

Am J Med Genet A. 2015 Nov;167A(11):2808-16. doi: 10.1002/ajmg.a.37268. Epub 2015 Aug 4.

PMID:
26238961
18.

Cell surface glycan engineering of neural stem cells augments neurotropism and improves recovery in a murine model of multiple sclerosis.

Merzaban JS, Imitola J, Starossom SC, Zhu B, Wang Y, Lee J, Ali AJ, Olah M, Abuelela AF, Khoury SJ, Sackstein R.

Glycobiology. 2015 Dec;25(12):1392-409. doi: 10.1093/glycob/cwv046. Epub 2015 Jul 7.

19.

Rapid dissemination of granular cell astrocytoma arising from periventricular stem cell regions in chronic multiple sclerosis.

Imitola J, Wagoner J, Khurana JS.

J Neurooncol. 2015 Aug;124(1):147-9. doi: 10.1007/s11060-015-1811-4. Epub 2015 May 24. No abstract available.

PMID:
26003876
20.

Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy.

Rasouli J, Ciric B, Imitola J, Gonnella P, Hwang D, Mahajan K, Mari ER, Safavi F, Leist TP, Zhang GX, Rostami A.

J Immunol. 2015 Jun 1;194(11):5085-93. doi: 10.4049/jimmunol.1403243. Epub 2015 Apr 27.

21.

Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration.

Orack JC, Deleidi M, Pitt D, Mahajan K, Nicholas JA, Boster AL, Racke MK, Comabella M, Watanabe F, Imitola J.

Stem Cells Transl Med. 2015 Mar;4(3):252-60. doi: 10.5966/sctm.2014-0133. Epub 2015 Jan 15. Review.

22.

Is no evidence of disease activity a realistic goal for patients with multiple sclerosis?

Imitola J, Racke MK.

JAMA Neurol. 2015 Feb;72(2):145-7. doi: 10.1001/jamaneurol.2014.3860. No abstract available.

PMID:
25531742
23.

The cerebrospinal fluid-stem cell interactions as target for regenerative therapy in neurological diseases.

Durvasula S, Imitola J.

Stem Cells Dev. 2015 Jan 15;24(2):145-6. doi: 10.1089/scd.2014.0572. No abstract available.

PMID:
25517016
24.

Fraternal twins with autism, severe cognitive deficit, and epilepsy: diagnostic role of chromosomal microarray analysis.

Imitola J, Walleigh D, Anderson CE, Jethva R, Carvalho KS, Legido A, Khurana DS.

Semin Pediatr Neurol. 2014 Jun;21(2):167-71. doi: 10.1016/j.spen.2014.04.027. Epub 2014 Apr 30.

PMID:
25149956
25.

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.

Nicholas JA, Boster AL, Imitola J, O'Connell C, Racke MK.

Drug Des Devel Ther. 2014 Jul 7;8:897-908. doi: 10.2147/DDDT.S50962. eCollection 2014. Review.

26.

First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.

Nicholas JA, Racke MK, Imitola J, Boster AL.

Ther Adv Chronic Dis. 2014 Mar;5(2):62-8. doi: 10.1177/2040622313514790. Review.

27.

Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration.

Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, Bassil R, Croci DO, Cerliani JP, Delacour D, Wang Y, Elyaman W, Khoury SJ, Rabinovich GA.

Immunity. 2012 Aug 24;37(2):249-63. doi: 10.1016/j.immuni.2012.05.023. Epub 2012 Aug 9.

28.

Multifocal CNS infiltration of chronic lymphocytic leukemia in the form of small-cell solid metastatic lesions.

Imitola J, Pitt K, Peoples JL, Krynska B, Sheikh H, Kesari S, Azizi SA.

J Neurooncol. 2012 Aug;109(1):213-5. doi: 10.1007/s11060-012-0869-5. Epub 2012 May 10. No abstract available.

PMID:
22573347
29.

Human glioma growth is controlled by microRNA-10b.

Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, Imitola J, Ligon KL, Kesari S, Esau C, Stephens RM, Tannous BA, Krichevsky AM.

Cancer Res. 2011 May 15;71(10):3563-72. doi: 10.1158/0008-5472.CAN-10-3568. Epub 2011 Apr 6.

30.

Reversible neural stem cell niche dysfunction in a model of multiple sclerosis.

Rasmussen S, Imitola J, Ayuso-Sacido A, Wang Y, Starossom SC, Kivisäkk P, Zhu B, Meyer M, Bronson RT, Garcia-Verdugo JM, Khoury SJ.

Ann Neurol. 2011 May;69(5):878-91. doi: 10.1002/ana.22299. Epub 2011 Mar 9.

31.

Brain metastasis from ovarian cancer: case report and review of the literature.

Hu XQ, Imitola J, Kim RY, Mahta A, Kesari S.

Med Oncol. 2012 Jun;29(2):1250-2. doi: 10.1007/s12032-011-9876-1. Epub 2011 Mar 6. Review.

PMID:
21380785
32.

Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice.

Imitola J, Côté D, Rasmussen S, Xie XS, Liu Y, Chitnis T, Sidman RL, Lin CP, Khoury SJ.

J Biomed Opt. 2011 Feb;16(2):021109. doi: 10.1117/1.3533312.

33.

Subventricular zone microglia transcriptional networks.

Starossom SC, Imitola J, Wang Y, Cao L, Khoury SJ.

Brain Behav Immun. 2011 Jul;25(5):991-9. doi: 10.1016/j.bbi.2010.11.002. Epub 2010 Nov 11.

34.

IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells.

Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, Bettelli E, Oukka M, van Snick J, Renauld JC, Kuchroo VK, Khoury SJ.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12885-90. doi: 10.1073/pnas.0812530106. Epub 2009 May 11.

35.

Paradoxical dysregulation of the neural stem cell pathway sonic hedgehog-Gli1 in autoimmune encephalomyelitis and multiple sclerosis.

Wang Y, Imitola J, Rasmussen S, O'Connor KC, Khoury SJ.

Ann Neurol. 2008 Oct;64(4):417-27. doi: 10.1002/ana.21457.

36.

Persistent inflammation alters the function of the endogenous brain stem cell compartment.

Pluchino S, Muzio L, Imitola J, Deleidi M, Alfaro-Cervello C, Salani G, Porcheri C, Brambilla E, Cavasinni F, Bergamaschi A, Garcia-Verdugo JM, Comi G, Khoury SJ, Martino G.

Brain. 2008 Oct;131(Pt 10):2564-78. doi: 10.1093/brain/awn198. Epub 2008 Aug 30.

37.

Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis.

Elyaman W, Kivisäkk P, Reddy J, Chitnis T, Raddassi K, Imitola J, Bradshaw E, Kuchroo VK, Yagita H, Sayegh MH, Khoury SJ.

Am J Pathol. 2008 Aug;173(2):411-22. doi: 10.2353/ajpath.2008.080142. Epub 2008 Jun 26.

38.

Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas.

Dietrich J, Imitola J, Kesari S.

Nat Clin Pract Oncol. 2008 Jul;5(7):393-404. doi: 10.1038/ncponc1132. Epub 2008 Jun 3. Review.

PMID:
18521117
39.

Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis.

Kivisäkk P, Imitola J, Rasmussen S, Elyaman W, Zhu B, Ransohoff RM, Khoury SJ.

Ann Neurol. 2009 Apr;65(4):457-69. doi: 10.1002/ana.21379.

40.

Neural stem cells and the future treatment of neurological diseases: raising the standard.

Imitola J, Khoury SJ.

Methods Mol Biol. 2008;438:9-16. doi: 10.1007/978-1-59745-133-8_2.

PMID:
18369745
41.

Mycosis fungoides with leptomeningeal involvement.

Wabulya A, Imitola J, Santagata S, Kesari S.

J Clin Oncol. 2007 Dec 10;25(35):5658-61. No abstract available.

PMID:
18065739
42.

Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury.

Esposito G, Imitola J, Lu J, De Filippis D, Scuderi C, Ganesh VS, Folkerth R, Hecht J, Shin S, Iuvone T, Chesnut J, Steardo L, Sheen V.

Hum Mol Genet. 2008 Feb 1;17(3):440-57. Epub 2007 Nov 5.

PMID:
17984171
43.

Prospects for neural stem cell-based therapies for neurological diseases.

Imitola J.

Neurotherapeutics. 2007 Oct;4(4):701-14. Review.

PMID:
17920551
44.
45.

Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function.

Xiao S, Najafian N, Reddy J, Albin M, Zhu C, Jensen E, Imitola J, Korn T, Anderson AC, Zhang Z, Gutierrez C, Moll T, Sobel RA, Umetsu DT, Yagita H, Akiba H, Strom T, Sayegh MH, DeKruyff RH, Khoury SJ, Kuchroo VK.

J Exp Med. 2007 Jul 9;204(7):1691-702. Epub 2007 Jul 2.

46.

Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration.

Chitnis T, Imitola J, Wang Y, Elyaman W, Chawla P, Sharuk M, Raddassi K, Bronson RT, Khoury SJ.

Am J Pathol. 2007 May;170(5):1695-712.

47.
48.

Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease.

Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, Fisher Y, Owens T, Weiner HL.

Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5048-53. Epub 2006 Mar 20.

49.

Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.

Zhu B, Guleria I, Khosroshahi A, Chitnis T, Imitola J, Azuma M, Yagita H, Sayegh MH, Khoury SJ.

J Immunol. 2006 Mar 15;176(6):3480-9. Erratum in: J Immunol. 2006 May 1;176(9):5683.

50.

Supplemental Content

Loading ...
Support Center